Cellnovo Press Release

Impressive report issued by Soleil Securities on Advent portfolio company Cellnovo

By Site Content Team22 March 2010January 6th, 2023No Comments

Press Release.

The link to this report has expired.

Previous PostMediGene reports additional phase II results of EndoTAGTM-1 for the treatment of triple receptor-negative breast cancer
Next Post4-Antibody announces long-term collaboration with Boehringer Ingelheim with a maximum value of EUR 177.5m (CHF 266m) for 4-Antibody

© 2026 Advent Life Sciences.